Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
The group will integrate IDT's oligo synthesis technology with 3CR's PCR Allele Competitive Extension (PACE) Genotyping Master Mix and expertise in developing assays.
IDT and Beijing-based ChosenMed plan to develop large pan-cancer panels as part of the Cancer Genome Atlas of China.
Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.
Early-access users have used IDT's rhAmpSeq technology to create genetic marker maps for plants and to validate off target events in gene editing.
CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.
The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.
Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.
The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.